{"entity":{"id":"nct05417321","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of HB0036 in non-small-cell lung cancer, run by Shanghai Huaota Biopharmaceutical Co., Ltd., now recruiting.","summary":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05417321 by Shanghai Huaota Biopharmaceutical Co., Ltd., with 80 participants planned, started 2022-08-25 and due to reach its primary completion in 2025-08-01. Interventions recorded: HB0036.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05417321","url":"https://clinicaltrials.gov/study/NCT05417321"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["hb0036"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05417321","phase":"1/2","setting":"A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","enrolled":80,"outcomes":[]},"route":"/trials/nct05417321/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"hb0036","kind":"drug","name":"HB0036","route":"/drugs/hb0036/"}]}}